<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style> Enap catalog › Details for: Linking intangible resources and competition
Normal view MARC view ISBD view

Linking intangible resources and competition

By: HAANES, Knut.
Contributor(s): FJELDSTAD, Oystein.
Material type: materialTypeLabelArticlePublisher: 2000European Management Journal 18, 1, p. 52-62Abstract: Recent strategy literature that intangible resources - in patticular competencies and relationships - are critical drivers of competitive advantage. However, there seems to be a lack of understanding of when certain types of competencies and relationships are most critical. This paper introduces a framework consisting of three fundamental levels of resource-competition . The framework is illustrated through the pharmaceutical industry. We argue that (1) biotech firms mainly engage in entrepreneurial competition; (2) traditional pharmaceutical firms - here referred to as big-pharma - increasingly undertake contractual competition and, finally (3) generic drug makers compete predominantly operationally. The paper argues that intangible resources contribute differently to competitive advantage depending on level of competition
Tags from this library: No tags from this library for this title. Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Collection Call number Status Date due Barcode
Periódico Biblioteca Graciliano Ramos
Periódico Not for loan

Recent strategy literature that intangible resources - in patticular competencies and relationships - are critical drivers of competitive advantage. However, there seems to be a lack of understanding of when certain types of competencies and relationships are most critical. This paper introduces a framework consisting of three fundamental levels of resource-competition . The framework is illustrated through the pharmaceutical industry. We argue that (1) biotech firms mainly engage in entrepreneurial competition; (2) traditional pharmaceutical firms - here referred to as big-pharma - increasingly undertake contractual competition and, finally (3) generic drug makers compete predominantly operationally. The paper argues that intangible resources contribute differently to competitive advantage depending on level of competition

There are no comments for this item.

Log in to your account to post a comment.

Click on an image to view it in the image viewer

Escola Nacional de Administração Pública

Escola Nacional de Administração Pública

Endereço:

  • Biblioteca Graciliano Ramos
  • Funcionamento: segunda a sexta-feira, das 9h às 19h
  • +55 61 2020-3139 / biblioteca@enap.gov.br
  • SPO Área Especial 2-A
  • CEP 70610-900 - Brasília/DF
<
Acesso à Informação TRANSPARÊNCIA

Powered by Koha